Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant

SourceYahoo Finance
Date Published03/24/2020
Author NamePR Newswire
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Ology Bioservices
Parent companyOlogy Bioservices
Type of work Manufacturing
Reshoring category:Reshoring
City reshored to:Plymouth Meeting
State(s) reshored to:PA
If relevant, work nearshored to:-
Product(s) reshoredDNA medicine
What domestic positive factors made reshoring more attractive?Eco-system synergies, Lead time/Time to market, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market
Find Reshoring Articles